Literature DB >> 31971998

Efficacy of combined CDK9/BET inhibition in preclinical models of MLL-rearranged acute leukemia.

Hannah McCalmont1, Ka Leung Li2, Luke Jones1, John Toubia2, Sarah C Bray3, Debora A Casolari2, Chelsea Mayoh1, Saumya E Samaraweera2, Ian D Lewis4, Rab K Prinjha5, Nicholas Smithers5, Shudong Wang6, Richard B Lock1, Richard J D'Andrea2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31971998      PMCID： PMC6988396          DOI： 10.1182/bloodadvances.2019000586

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  25 in total

1.  Licensed to elongate: a molecular mechanism for MLL-based leukaemogenesis.

Authors:  Man Mohan; Chengqi Lin; Erin Guest; Ali Shilatifard
Journal:  Nat Rev Cancer       Date:  2010-09-16       Impact factor: 60.716

2.  Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4.

Authors:  Zhiyuan Yang; Jasper H N Yik; Ruichuan Chen; Nanhai He; Moon Kyoo Jang; Keiko Ozato; Qiang Zhou
Journal:  Mol Cell       Date:  2005-08-19       Impact factor: 17.970

Review 3.  Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet.

Authors:  Miguel A Sanz; Pierre Fenaux; Martin S Tallman; Elihu H Estey; Bob Löwenberg; Tomoki Naoe; Eva Lengfelder; Hartmut Döhner; Alan K Burnett; Sai-Juan Chen; Vikram Mathews; Harry Iland; Eduardo Rego; Hagop Kantarjian; Lionel Adès; Giuseppe Avvisati; Pau Montesinos; Uwe Platzbecker; Farhad Ravandi; Nigel H Russell; Francesco Lo-Coco
Journal:  Blood       Date:  2019-02-25       Impact factor: 22.113

4.  Super-enhancers in the control of cell identity and disease.

Authors:  Denes Hnisz; Brian J Abraham; Tong Ihn Lee; Ashley Lau; Violaine Saint-André; Alla A Sigova; Heather A Hoke; Richard A Young
Journal:  Cell       Date:  2013-10-10       Impact factor: 41.582

5.  Functional heterogeneity of genetically defined subclones in acute myeloid leukemia.

Authors:  Jeffery M Klco; David H Spencer; Christopher A Miller; Malachi Griffith; Tamara L Lamprecht; Michelle O'Laughlin; Catrina Fronick; Vincent Magrini; Ryan T Demeter; Robert S Fulton; William C Eades; Daniel C Link; Timothy A Graubert; Matthew J Walter; Elaine R Mardis; John F Dipersio; Richard K Wilson; Timothy J Ley
Journal:  Cancer Cell       Date:  2014-03-06       Impact factor: 31.743

Review 6.  The MYC Enhancer-ome: Long-Range Transcriptional Regulation of MYC in Cancer.

Authors:  Olga Lancho; Daniel Herranz
Journal:  Trends Cancer       Date:  2018-11-02

7.  Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice.

Authors:  Erwin M Lee; Dean Yee; Samantha J Busfield; Julie F McManus; Nik Cummings; Gino Vairo; Andrew Wei; Hayley S Ramshaw; Jason A Powell; Angel F Lopez; Ian D Lewis; Martin N McCall; Richard B Lock
Journal:  Haematologica       Date:  2015-07       Impact factor: 9.941

8.  Selective inhibition of tumor oncogenes by disruption of super-enhancers.

Authors:  Jakob Lovén; Heather A Hoke; Charles Y Lin; Ashley Lau; David A Orlando; Christopher R Vakoc; James E Bradner; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2013-04-11       Impact factor: 41.582

9.  Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias.

Authors:  Ivana Gojo; Mariola Sadowska; Alison Walker; Eric J Feldman; Swaminathan Padmanabhan Iyer; Maria R Baer; Edward A Sausville; Rena G Lapidus; Da Zhang; Yali Zhu; Ying-Ming Jou; Jennifer Poon; Karen Small; Rajat Bannerji
Journal:  Cancer Chemother Pharmacol       Date:  2013-08-15       Impact factor: 3.333

10.  Combined BRD4 and CDK9 inhibition as a new therapeutic approach in malignant rhabdoid tumors.

Authors:  Natalia Moreno; Till Holsten; Julius Mertins; Annabelle Zhogbi; Pascal Johann; Marcel Kool; Michael Meisterernst; Kornelius Kerl
Journal:  Oncotarget       Date:  2017-06-21
View more
  9 in total

Review 1.  Transcription associated cyclin-dependent kinases as therapeutic targets for prostate cancer.

Authors:  Theodora A Constantin; Kyle K Greenland; Anabel Varela-Carver; Charlotte L Bevan
Journal:  Oncogene       Date:  2022-05-14       Impact factor: 8.756

Review 2.  MYC's Fine Line Between B Cell Development and Malignancy.

Authors:  Oriol de Barrios; Ainara Meler; Maribel Parra
Journal:  Cells       Date:  2020-02-24       Impact factor: 6.600

3.  Acute Myeloid Leukemia: From Biology to Clinical Practices Through Development and Pre-Clinical Therapeutics.

Authors:  Xavier Roussel; Etienne Daguindau; Ana Berceanu; Yohan Desbrosses; Walid Warda; Mathieu Neto da Rocha; Rim Trad; Eric Deconinck; Marina Deschamps; Christophe Ferrand
Journal:  Front Oncol       Date:  2020-12-09       Impact factor: 6.244

Review 4.  The Molecular 'Myc-anisms' Behind Myc-Driven Tumorigenesis and the Relevant Myc-Directed Therapeutics.

Authors:  Jessica McAnulty; Analisa DiFeo
Journal:  Int J Mol Sci       Date:  2020-12-13       Impact factor: 5.923

5.  An Orally Bioavailable and Highly Efficacious Inhibitor of CDK9/FLT3 for the Treatment of Acute Myeloid Leukemia.

Authors:  Abel Tesfaye Anshabo; Laychiluh Bantie; Sarah Diab; Jimma Lenjisa; Alemwork Kebede; Yi Long; Gary Heinemann; Jasmine Karanjia; Benjamin Noll; Sunita K C Basnet; Manjun Li; Robert Milne; Hugo Albrecht; Shudong Wang
Journal:  Cancers (Basel)       Date:  2022-02-22       Impact factor: 6.639

Review 6.  Plasmacytoid Dendritic Cells, a Novel Target in Myeloid Neoplasms.

Authors:  Xavier Roussel; Francine Garnache Ottou; Florian Renosi
Journal:  Cancers (Basel)       Date:  2022-07-21       Impact factor: 6.575

Review 7.  Targeting CDK9 for Anti-Cancer Therapeutics.

Authors:  Ranadip Mandal; Sven Becker; Klaus Strebhardt
Journal:  Cancers (Basel)       Date:  2021-05-01       Impact factor: 6.639

Review 8.  Novel agents targeting leukemia cells and immune microenvironment for prevention and treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.

Authors:  Wei Shi; Weiwei Jin; Linghui Xia; Yu Hu
Journal:  Acta Pharm Sin B       Date:  2020-06-30       Impact factor: 11.413

Review 9.  CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents.

Authors:  Abel Tesfaye Anshabo; Robert Milne; Shudong Wang; Hugo Albrecht
Journal:  Front Oncol       Date:  2021-05-10       Impact factor: 6.244
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.